Keeping It Real: Real-World Brodalumab Outcomes in the Conte…
Emerging
0
Citations4
Refs2026
Year
Search Works
Work Details
- DOI 10.25251/a384hv18
- OpenAlex ID W7211936489
- Type Article
- Language EN
- Published 08 Sep 2026
- Volume 10 (4)
- Pages s800
- Source SKIN The Journal of Cutaneous Medicine
- Countries 2
- Institutions 7
- Added 09 Sep 2026
- Updated 28 Oct 2026
External Links
MENU
0
Keeping It Real: Real-World Brodalumab Outcomes in the Context of Pivotal Trials for Moderate-to-Severe Plaque Psoriasis
Article 2026 EN Diamond
Introduction Brodalumab is the only interleukin-17 (IL-17) receptor A blocker approved for moderate-to-severe plaque psoriasis and blocks downstream signaling of multiple IL-17 isoforms including IL-17A, IL-17F, IL-17C, IL-17E, and IL-17A/F. Here, we contextualize effectiveness and safety of brodalumab in adult patients in the Canadian Real-World Evidence (CARE) study alongside results from pivota…
0
Citations
4
References
6
Authors
0.00
FWCI
Topics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
6 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Marni Wiseman | University of Manitoba (CA) | |
| 2 | Sunil Kalia | University of British Columbia (CA) | |
| 3 | Charles W Lynde | University of Toronto (CA) Lynde Centre for Dermatology (CA) +1 | |
| 4 | David Adam | University of Toronto (CA) Probity Medical Research (CA) | — |
| 5 | April W. Armstrong | University of California, Los … (US) | |
| 6 | Mark Lebwohl | Icahn School of Medicine at Mo… (US) |
Related Works
10Data: OpenAlex